Mitochondrial DNA mutations in head and neck cancer are infrequent and lack prognostic utility by Challen, C et al.
Mitochondrial DNA mutations in head and neck cancer are
infrequent and lack prognostic utility
C Challen
1, H Brown
2, C Cai
1, G Betts
3, I Paterson
4, P Sloan
1, C West
3, M Birch-Machin
2,5 and M Robinson*,1,5
1Centre for Oral Health Research, School of Dental Sciences, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4BW, UK;
2Institute of
Cellular Medicine, Newcastle University, Newcastle-upon-Tyne NE1 7RU, UK;
3School of Cancer and Enabling Sciences, University of Manchester, Christie
Hospital NHS Trust, Manchester M20 4BX, UK;
4School of Life Sciences, University of Westminster, London W1B 2UW, UK
BACKGROUND: Mitochondrial DNA (mtDNA) mutations occur in head and neck squamous cell carcinoma (HNSCC) and are most
frequently detected in the displacement-loop (D-loop) region. The D-loop is considered to be important because it controls
mitochondrial gene expression and mtDNA replication. There is currently no evidence that mtDNA mutations can be used as
prognostic or predictive biomarkers in HNSCC.
METHODS: We used denaturing high performance liquid chromatography to screen the entire mitochondrial genome of six oral
squamous cell carcinoma-derived cell lines and then focused on detecting D-loop abnormalities in 34 HNSCC tissue samples.
RESULTS: Mitochondrial DNA mutations are not ubiquitous in HNSCC because only half of the cell lines had detectable mtDNA
abnormalities following screening of the entire mitochondrial genome and only 18% (6 of 34) of tissue samples had D-loop
mutations. There was no correlation between D-loop mutations and determinates of clinical outcome; specifically, tumour stage and
the expression of hypoxia-inducible genes included in a highly prognostic hypoxia metagene.
CONCLUSIONS: Taken together, these data suggest that mtDNA D-loop mutations are stochastic events that may not significantly
influence the biology of HNSCC and supports the hypothesis that mtDNA mutations in cancer represent bystander genotoxic
damage as a consequence of tumour development and progression.
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Head and neck squamous cell carcinoma (HNSCC) is a major
world health problem; estimates indicate that there are over
400000 new cases diagnosed each year (Cancer Research UK,
2010). Typically, most patients present with advanced disease
which has a poor prognosis and more than a third of the patients
die within 5 years of diagnosis (Cancer Research UK, 2010). The
search for prognostic and predictive biomarkers is a key strategy
that could be used to improve the management of patients with
HNSCC.
Somatic mutations in mitochondrial DNA (mtDNA) have been
increasingly observed in human cancers and have been proposed
as important oncological biomarkers (Jakupciak et al, 2005;
Chatterjee et al, 2006). Mitochondrial DNA mutations have been
detected in HNSCCs and their premalignant counterparts (Ha et al,
2002; Chatterjee et al, 2006; Mithani et al, 2007). Mutations occur
throughout the mitochondrial genome, but are most frequently
detected in the displacement-loop (D-loop) region; around a third
of HNSCC samples harbour D-loop mutations (range 2–67%;
Table 1; Fliss et al, 2000; Sanchez-Cespedes et al, 2001; Tan et al,
2003; Lie `vre et al, 2006; Pai et al, 2006; Prior et al, 2006; Zhou et al,
2006, 2007; Dasgupta et al, 2010). The D-loop region is considered
to be important because it is the major control site for mtDNA
expression and it is also involved in mtDNA replication (Taanman,
1999).
The biological significance of mtDNA mutations in cancer
remains unclear (Chatterjee et al, 2006). Nevertheless, evidence is
emerging that mtDNA damage has direct effects on the malignant
phenotype and that these effects are mediated by reactive oxygen
species (ROS; Petros et al, 2005; Ishikawa et al, 2008). Interestingly,
mitochondrial ROS contributes to stabilisation of HIF-1a protein
in hypoxia, leading to the proposal that ROS act as ‘oxygen
sensors’ to trigger the hypoxia response (Klimova and Chandel,
2008). Recently, Sun et al (2009) showed expression of mutant
mitochondrial NADH dehydrogenase 2 (ND2) in a HNSCC-derived
cell line increased ROS production, which resulted in HIF-1a
stabilisation and a shift to aerobic glycolysis. Furthermore,
persistent increased levels of ROS, in the context of mutated
mtDNA, may represent one of the mechanisms that drive genomic
instability. Reactive oxygen species are DNA damaging agents that
could perpetuate mtDNA damage and also cause genotoxic damage
to the nucleosome (Lee and Wei, 2009). The link between mtDNA
abnormalities, increased ROS and hypoxia may be particularly
significant in HNSCC because of the association between hypoxia
and an adverse prognosis in the disease (Nordsmark et al, 2005;
Winter et al, 2007; Buffa et al, 2010).
In the present study, we screened the entire mitochondrial
genome of six oral squamous cell carcinoma-derived cell lines
for mtDNA deletions and mutations using denaturing high
performance liquid chromatography (DHPLC) and then focused
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samples. For the first time, we examined the relationship between
mtDNA mutations and the expression of hypoxia-inducible genes
in HNSCC tissue samples.
MATERIALS AND METHODS
Cell lines
Six human oral squamous cell carcinoma-derived cell lines were
used (Table 2). Four of the cell lines have been described
previously (Prime et al, 1990). The two new cell lines (H764A
and H764B) were a kind gift of Professor S Prime (University of
Bristol). HaCaT cells (Boukamp et al, 1990) and primary cultures
of normal oral keratinocytes grown from explanted biopsy
material were used as controls for high-throughput screening of
cell line mtDNA. Cell line matched normal DNA was used to
precisely characterise ‘screen-detected’ mtDNA abnormalities.
Genomic DNA extracted from contiguous fibroblast cultures was
available for four of the cell lines (H314, H357, H400, and H413;
Drugan et al, 1997) and DNA extracted from formalin-fixed
paraffin-embedded tissue (striated muscle) was used for H764A
and H764B.
Tissue samples
The tissue samples (tumour and normal mucosa) were derived
from patients with previously untreated primary HNSCC. The
research was given a favourable opinion from the Newcastle and
North Tyneside 2 Research Ethics Committee (Reference
09/H0907/58). The clinical features of the samples are summarised
in Table 3. The tissues were harvested at the time of surgical
resection and were immediately placed in RNAlater (Applied
Biosystems, Warrington, UK) before storage in liquid nitrogen.
Preparation of DNA
Genomic DNA was extracted from cell pellets using a standard
laboratory kit (QIAGEN Ltd, Crawley, UK). DNA was extracted
from homogenised tissue samples using Tri Reagent (Sigma-
Aldrich, Gillingham, UK) and cleaned using a standard laboratory
kit (QIAGEN). Extracted DNA samples were diluted to 200ngml
 1
for use in downstream analysis.
Long template PCR
Genomic DNA from the cell lines were screened for large-scale
mtDNA deletions using the Expand Long Template PCR System as
previously described (Roche Diagnostics Ltd, Burgess Hill, UK;
Ray et al, 2000). DNA from a patient with mitochondrial myopathy,
characterised by a 4976-bp mtDNA deletion, was used as a positive
control (kind gift of Professor R Taylor, Newcastle University).
Mitoscreen assay and DHPLC analysis
Genomic DNA samples were screened for small deletions, insertions,
and point mutations using the Mitoscreen Assay System (Trans-
genomic Ltd, Glasgow, UK). The system comprises 19 overlapping
primer sets that amplify the entire mitochondrial genome.
Table 1 Prevalence of D-loop mutations in head and neck squamous cell
carcinoma
Study
No. of
patients
No. with
D-loop
mutations
Percentage
%
Fliss et al (2000) 13 3 23
Sanchez-Cespedes et al (2001) 51 19 37
Tan et al (2003) 18 12 67
Lie `vre et al (2006) 109 23 21
Pai et al (2006) 67 41 61
Prior et al (2006) 30 16 53
Zhou et al (2006) 7 3 43
Zhou et al (2007) 83 24 29
Dasgupta et al (2010) 50 1 2
Total 428 142 33
Table 2 Derivation of the human oral squamous cell carcinoma-derived
cell lines (Prime et al, 1990)
Cell line Age Sex Site Grade Stage
H314 82 M FOM MD II
H357 74 M T WD I
H400 55 F AP MD II
H413 53 F BM MD II
H764A 70 M FOM MD IV
H764B 70 M LN MD IV
Abbreviations: AP¼alveolar process; BM¼buccal mucosa; FOM¼floor of mouth;
LN¼lymph node; T¼tongue; MD¼moderately differentiated; WD¼well-
differentiated squamous cell carcinoma.
Table 3 The clinical features of squamous cell carcinoma tissue samples
Sample no. Age Sex Site Grade Stage
34 73 M Oral cavity MD IVA
35 65 M Hypopharynx MD IVA
38 60 F Oral cavity MD IVA
41 38 M Larynx MD IVA
42 71 M Hypopharynx MD IVA
43 58 M Hypopharynx Basaloid IVA
44 68 F Oral cavity MD II
45 68 M Oral cavity MD II
46 44 M Oropharynx Basaloid IVA
47 69 M Oral cavity PD IVA
51 59 M Oral cavity MD I
54 58 M Larynx PD IVA
59 38 F Oral cavity MD III
60 64 M Oral cavity MD I
61 44 M Oral cavity MD II
62 70 M Larynx NR IVA
63 59 M Oropharynx Basaloid IVA
64 54 M Oropharynx Basaloid IVA
65 70 M Larynx MD II
67 56 M Oral cavity MD IVA
68 64 M Larynx MD IVA
70 66 M Oropharynx Basaloid IVA
71 53 M Oral cavity MD III
73 55 M Hypopharynx MD III
75 76 F Larynx MD IVA
76 43 M Oral cavity MD II
78 53 M Larynx MD IVA
80 63 F Larynx MD IVA
82 63 M Larynx PD IVA
83 56 M Larynx PD IVA
85 57 F Oral cavity MD IVA
87 54 M Oral cavity MD II
88 61 F Oral cavity MD IVA
89 69 M Hypopharynx MD IVA
Abbreviations: MD¼moderately differentiated; PD¼poorly differentiated;
NR¼not recorded.
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sReactions were carried out according to the manufacturer’s
standard protocol. Briefly, PCRs were performed in 20–40ml
reactions containing 100ng of genomic DNA, 0.15mM of each
primer and 2.5 units of Optimase polymerase (Transgenomic Ltd).
In all, 15 of the 19 primer sets generated large amplicons that
required digestion with restriction enzymes before heteroduplex
formation. Heteroduplexed DNA was analysed by DHPLC on a
Transgenomic Wave DNA Fragment Analysis System 3500 using
Navigator software (Transgenomic Ltd).
Automated sequencing
Denaturing high performance liquid chromatography fractions
harbouring putative mtDNA abnormalities were eluted and
dehydrated using a DNA concentrator (Gyrovap, Howe and Co.,
London, UK). DNA was resuspended in 5ml of water and
reamplified using appropriate primer sets. The PCR products
were resolved on a 2% low melting point agarose gel (NuSieve 3.1
Agarose, Lonza Rockland Inc., Rockland, ME, USA) containing
ethidium bromide. The DNA band representing the amplicon was
excised from the gel and the DNA was extracted using the
QIAquick Gel Extraction Kit (QIAGEN). The purified DNA was
eluted in 30ml of Tris/EDTA buffer. The sequencing reaction was
carried out using the GenomeLab Dye Terminator Cycle Sequen-
cing Kit (Beckman Coulter UK Ltd, High Wycombe, UK)
according to the manufacturer’s protocol. The products were run
on a Beckman CEQ Genetic Analysis System 8000 (Beckman
Coulter). Sequences were visualised using MacVector 7.0 software
(Oxford Molecular Ltd, Oxford, UK) and compared with the
mtDNA revised Cambridge reference sequence (MITOMAP, 2010).
Hypoxia-inducible gene expression
Tissue samples were prepared for quantitative real-time PCR
(qRT–PCR) as described previously (Winter et al,2 0 0 7 ) .Q u a n t i -
tative real-time PCR for CA9, PGAM1, SLC2A1, and VEGFA was
performed using Taqman assays (Applied Biosystems) on a low-
density array format with normalisation to appropriate endogenous
reference genes. Cycle threshold (Ct) values were converted to a
measure of gene expression relative to the endogenous reference
gene expression using the 2
 DCt formula before statistical analysis as
previously described (Livak and Schmittgen, 2001).
RESULTS
Screening of cell lines for mtDNA abnormalities
None of the cell lines contained any large-scale mtDNA deletions
(data not shown). Using DNA extracted from normal oral
keratinocytes and HaCaT cells as a comparator, DHPLC profiles
from the cell line DNA had a number of abnormalities. The
abnormalities included broader wave profiles, peak shifts, and a
change in the number of fragments in those samples subject to
restriction enzyme digestion. Whole mitochondrial genome
screening of the six cell lines generated 114 amplicons representing
around 100kb of DNA. A total of 17 mtDNA abnormalities were
detected using this method and abnormalities were identified in all
of the cell lines.
Characterisation of cell line mtDNA abnormalities by
sequence analysis
Sequencing of ‘screen-detected’ mtDNA abnormalities in the cell
lines alongside matched normal DNA demonstrated that around
half of the abnormalities (8 of 17) were common to both samples
and represented mtDNA polymorphisms. H357, H400, and H413
had polymorphic mtDNA, but no somatic mtDNA mutations.
By contrast, H314 had a complex mtDNA genotype with nine
homoplasmic point mutations located in two regions of
the mitochondrial genome, namely cytochrome oxidase I and the
D-loop (Table 4). There were three base pair changes in
the cytochrome oxidase I gene of H314 that were not present in
the matched fibroblast DNA. The base changes were all synon-
ymous and there was no predicted change in the amino-acid
sequence of the codon. Six point mutations were detected in the D-
loop; the matched fibroblasts followed the revised Cambridge
reference sequence (MITOMAP, 2010). The base pair changes were
all located in hypervariable segment 1 (HVS1) of the D-loop.
H764A and H764B, cell lines derived from the same patient
representing a primary oral squamous cell carcinoma and a
corresponding lymph node metastasis, respectively, had two
sequence abnormalities not detected in the matched normal
DNA. The first was a homoplasmic 50bp deletion in the D-loop
between nucleotide positions 298/306 and 348/356; the breakpoints
were flanked by a 9-bp repeat sequence 50-CCAAACCCC-30
(Figure 1). The deletion was located in a non-coding, control
region of the D-loop covering the mtTF1-binding site, replication
primer, and conserved sequence blocks 2 and 3. An identical 50bp
deletion has previously been reported in four gastric cancers and a
hepatocellular carcinoma (Burgart et al, 1995; Lee et al, 2004). The
second sequence abnormality was a homoplasmic point mutation
in the D-loop; G-A at nucleotide 16129 in HVS1.
Screening tissue samples for mtDNA abnormalities in the
D-loop region
Twenty-two abnormalities were detected following screening of
102 amplicons in 34 HNSCC with matched normal mucosal
Table 4 Mitochondrial DNA mutations in H314 cells
Mitochondrial
gene/region
D-loop
region
Nucleotide
position
mtDNA
rCRS
Control H314
fibroblasts
Tumour
H314
Mutation
status
Reported
previously
a
COI NA 6152 T T C HM No
COI NA 6179 G G A HM No
COI NA 6180 G G A HM No
D-loop HVS1 16064 T T C HM No
D-loop HVS1 16093 T T C HM No
D-loop HVS1 16094 T T C HM No
D-loop HVS1 16102 T T A HM No
D-loop HVS1 16124 T T G HM No
D-loop HVS1 16145 G G A HM No
Abbreviations: COI¼cytochrome oxidase I (np 5904–7445); D-loop¼displacement-loop (np 16024–576); HVS1¼hypervariable segment 1; NA¼not applicable;
mtDNA rCRS¼mitochondrial DNA revised Cambridge reference sequence (MITOMAP, 2010); HM¼homoplasmic.
aMutation reported on a publically available database
(MITOMAP, 2010).
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ssamples. Sequencing of the variant amplicons demonstrated
that 15 of the samples contained known sequence variants
(polymorphisms) that were identical in the normal and tumour
DNA (data not shown). Eight somatic mutations were detected in
seven samples; sample 85 contained two mutations (Table 5). The
majority (6 of 8) of the mutations were located in the D-loop; two
were located in 12S rRNA gene. Eighteen percent (6 of 34) of the
samples harboured a D-loop mutation and there was a mixture of
homoplasmic and heteroplasmic mutations (Table 5; Figure 2).
One of the D-loop mutations (146 T-C) has previously been
reported in ovarian and prostate cancer (Figure 2A; MITOMAP,
2010).
Relationship of D-loop mutations to clinical parameters
and hypoxia-inducible genes
The samples with D-loop mutations did not have any distinct
clinico-pathological characteristics; there was no clear association
with patient age, gender, tumour location, grade, and stage.
Analysis of overall survival showed no difference for patients with
D-loop mutations compared with those patients with normal
D-loop sequences. We investigated the relationship between
mtDNA D-loop mutations and the expression of four hypoxia-
inducible genes included in a highly prognostic hypoxia metagene
(CA9, PGAM1, SLC2A1, and VEGFA; Winter et al, 2007; Buffa et al,
2010). For each of the four genes, the samples with D-loop
mutations (n¼6) had lower mean gene expression levels when
compared with those samples that had normal D-loop sequences
356 348 306 298
DN
ND
D
Nuc. pos.
Sequence CCA CCAAACCCC CCC CTG CCAAACCCC AAA
50bp deletion
Figure 1 H764A and H764B cell lines harboured a homoplasmic 50bp
deletion in the D-loop region. The deletion (D) was identified by DHPLC,
DNA electrophoresis, and DNA sequencing (from left to right,
respectively; N¼matched normal DNA sample). The deletion was located
between nucleotide positions (nuc. pos.) 298/306 and 348/356; the
breakpoints were flanked by a 9-bp repeat sequence 50-CCAAACCCC-30.
Table 5 Mitochondrial mutations detected in head and neck squamous cell carcinoma tissue samples
Case
Mitochondrial
gene/region
D-loop
region
Nucleotide
position
mtDNA
rCRS
Control
tissue Tumour
Mutation
status
Reported
previously
a
43 D-loop HVS2 153 A A G HM No
47 D-loop H-strand origin 374 A A A/G HT No
64 12S rRNA NA 796 G G A HM No
83 D-loop HVS2 265 T T T/A HT No
85 12S rRNA NA 779 T T T/G HT No
85 D-loop HVS1 16129 G A G/A HT No
87 D-loop HVS2 146 T T C HM Ovarian carcinoma
Prostate tumour
88 D-loop HVS1 16145 G G G/A HT No
Abbreviations: HVS1/2¼hypervariable segment 1/2; NA¼not applicable; mtDNA rCRS¼mitochondrial DNA revised Cambridge reference sequence (MITOMAP, 2010);
HM¼homoplasmic; HT¼heteroplasmic.
aMutation reported on a publically available database (MITOMAP, 2010).
A *
* B
Figure 2 D-loop mutations in head and neck squamous cell carcinoma
tissue samples. (A) Homoplasmic mutation at 146 T-C (*) in sample 87.
Sequence shown from nucleotide position 141–151 for normal sample
(left panel) and tumour sample (right panel). (B) Heteroplasmic mutation
at 374 A-G (*) in sample 47. Sequence shown from nucleotide position
369–379 for normal sample (left panel) and tumour sample (right panel).
In the tumour, there are two peaks at 374; there is a mixture of A and G
nucleotides.
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in hypoxia gene expression between the two groups (CA9 0.03 vs
0.01, P¼0.30; PGAM1 0.24 vs 0.18, P¼0.29; SLC2A1 0.48 vs 0.13,
P¼0.08; VEGFA 0.07 vs 0.03, P¼0.19; parametric t-test, SPSS
Statistics 17.0, SPSS Inc., Chicago, IL, USA; Figure 3).
DISCUSSION
In the current study, we screened oral squamous cell carcinoma-
derived cell lines and HNSCC tissue samples for mtDNA
mutations. Large-scale deletions of the mitochondrial genome
have been reported in oral SCC (Tan et al, 2003; Shieh et al, 2004),
however, our study and others (Zhou et al, 2007) have not been
able to detect such abnormalities and therefore the significance of
large-scale mtDNA deletions in HNSCC is unclear. We used
DHPLC to screen samples for small-scale deletions, insertions, and
point mutations. The majority of studies investigating mtDNA
abnormalities in HNSCC have focused on small regions of the
mitochondrial genome using PCR and sequencing (Fliss et al,
2000; Sanchez-Cespedes et al, 2001; Lie `vre et al, 2006; Pai et al,
2006; Prior et al, 2006). Sequencing alone lacks sensitivity, because
the technique only reliably identifies mutant species when they
represent at least 25% of the amplicons in the sequencing reaction.
By contrast, DHPLC is highly sensitive and detects mutations at
very low thresholds; o5% (Birket and Birch-Machin, 2007).
Denaturing high performance liquid chromatography also benefits
from high specificity; identical DHPLC profiles between matched
tumour and normal DNA effectively excludes mutation (Van den
Bosch et al, 2000). The combination of DHPLC analysis and
sequencing of enriched amplicon fractions is likely to have
optimised mutation detection in our study.
We found that mtDNA mutations are not ubiquitous in HNSCC
because half of the cell lines had no detectable mtDNA
abnormalities following screening of the entire mitochondrial
genome and only a small proportion (18%) of the HNSCC tissue
samples had D-loop mutations. Pooled data from nine studies that
looked for D-loop mutations in over 400 HNSCCs indicate that
around a third of HNSCCs harbour D-loop mutations; however,
there is wide variation between different studies (range 2–67%;
Table 1). The latter may reflect differences in the methods of
mutation detection or the intrinsic genetic heterogeneity of
HNSCCs. Significantly, our data are comparable with the largest
series examined to date (n¼109; Lie `vre et al, 2006), which
detected D-loop mutations in only 21% of the samples.
The D-loop is considered to be particularly important because it
controls mitochondrial gene expression and it is involved in
mtDNA replication (Taanman, 1999). More recently, there is
evidence that the D-loop has a functional role in the formation of
mitochondrial nucleoids and the organisation of mtDNA during
segregation and replication (He et al, 2007; Holt et al, 2007). Of the
mutations detected in the current study, the majority were T-C,
G-A base transitions, which are associated with oxidative damage
(Fliss et al, 2000; Zhou et al, 2007) and raise the possibility that
ROS have a pivotal role in perpetuating mtDNA damage. While,
elevated levels of ROS are known to stabilise HIF-1a and trigger
the hypoxia response (Klimova and Chandel, 2008), we were
unable to demonstrate a correlation between mtDNA mutations
and hypoxia-inducible gene expression.
The 50-bp deletion identified in the D-loop of both H764A
and its corresponding lymph node metastasis, H764B, has
previously been reported in gastric adenocarcinomas and hepato-
cellular carcinomas (Burgart et al, 1995; Lee et al, 2004).
Furthermore, this small-scale deletion was also present in the
metastases of two of the gastric cancers (Burgart et al, 1995). These
findings are consistent with the concept of clonal expansion and
conservation of mtDNA mutations during tumour progression.
The functional significance of the deletion is unknown;
however, one possible mechanism is that the deletion affects
nucleoid formation, by interfering with ATAD3 binding, leading to
altered mtDNA copy number (Holt et al, 2007). Increased mtDNA
copy number has been described in HNSCCs (Kim et al, 2004) and
is also associated with increased oxidative stress (Lee and
Wei, 2009). These factors may account for the accumulation of
the deletion to homoplasmic levels and its persistence during
tumour progression.
There are a number of studies which indicate that D-loop
mutations have prognostic significance. Studies in non-small cell
lung cancer, colorectal cancer, and breast cancer showed
D-loop mutations are associated with poor prognosis (Matsuyama
et al, 2003; Lie `vre et al, 2005; Tseng et al, 2006). The only study in
HNSCC found no correlation between D-loop mutations and
prognosis or response to chemotherapy in 109 patients (Lie `vre
et al, 2006). Similarly, in the present study, there was no
obvious correlation between D-loop mutations and prognostic
indicators, specifically, tumour stage and the expression of
hypoxia-inducible genes included in a highly prognostic hypoxia
metagene (Winter et al, 2007; Buffa et al, 2010). These data are
consistent with other studies in a variety of other cancers
(oesophagus, gastric, lung, and ovarian), showing no correlation
between mtDNA abnormalities with clinico-pathological features,
which limits their utility as prognostic biomarkers in these
diseases (Lee and Wei, 2009).
In conclusion, our study indicates that mtDNA mutations are
infrequent in HNSCC, but most commonly located in the D-loop
region. Displacement-loop mutations are likely to be stochastic
events (i.e., subject to the variation of chance) that may not
significantly influence the biology of HNSCC. Our data support the
hypothesis that mtDNA mutations in cancer represent bystander
genotoxic damage as a consequence of tumour development and
progression (Taylor and Turnbull, 2005).
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